Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HCV+ patients with cryoglobulinemia Vasculitis~2. resistant to conventional therapy (i.e. antiviral therapy and/or immunosuppressors).~3. Vasculitis is defined according to international criteria: chronic HCV infection (HCV RNA+),~4. serum cryoglobulin superior or equal to 0.05g/l in at least two determinations,~5. presence of the triad purpura-arthralgia-asthenia and/or biopsy proven Vasculitis (kidney, nerve or skin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): it is a single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).